Connect with us

Published

on

Neuralink logo displayed on a phone screen, a silhouette of a paper in shape of a human face and a binary code displayed on a screen are seen in this multiple exposure illustration photo taken in Krakow, Poland on December 10, 2021.

Jakub Porzycki | Nurphoto | Getty Images

Elon Musk’s health tech venture Neuralink shared updates to its brain-implant technology during a “show and tell” recruitment event Wednesday night. Musk said during the event that he plans to get one of the implants himself.

Musk said two of the company’s applications will aim to restore vision, even for people who were born blind, and a third application will focus on the motor cortex by restoring “full body functionality” for people with severed spinal cords. “We’re confident there are no physical limitations to restoring full body functionality,” Musk said.

Neuralink could begin to test the motor cortex technology in humans in as soon as six months, Musk said.

“Obviously, we want to be extremely careful and certain that it will work well before putting a device in a human, but we’re submitted, I think, most of our paperwork to the FDA,” he said.

But he also claimed he plans to get one himself. “You could have a Neuralink device implanted right now and you wouldn’t even know. I mean, hypothetically. In one of these demos, in fact, in one of these demos, I will,” he said. He reiterated that on Twitter after the event.

Since none of Neuralinks’ devices have been tested on humans or approved by the FDA, Wednesday’s announcements warrant skepticism, said Xing Chen, assistant professor in the Department of Ophthalmology at the University of Pittsburgh School of Medicine.

“Neuralink is a company, it doesn’t have to answer to shareholders,” she told CNBC. “I don’t know how much oversight is involved, but I think it’s very important for the public to always keep in mind that before anything has been approved by the FDA, or any governmental regulatory body, all claims need to be very, very skeptically examined.”

Neuralink was founded in 2016 by Musk and a group of other scientists and engineers. It strives to develop brain-computer interfaces, or BCIs, that connect the human brain to computers that can decipher neural signals.

Musk invested tens of millions of his own personal wealth into the company and has said, without evidence, that Neuralink’s devices could enable “superhuman cognition,” enable paralyzed people to operate smartphones or robotic limbs with their minds someday, and “solve” autism and schizophrenia.

The company’s presentation Wednesday echoed these lofty ambitions, as Musk claimed that “as miraculous as it may sound, we’re confident that it is possible to restore full body functionality to someone who has a severed spinal cord.”

Musk showed footage of a monkey with a computer chip in its skull playing “telepathic video games,” which Neuralink first debuted over a year ago. The billionaire, who is also the CEO of Tesla, SpaceX and the new owner of Twitter, said at the time that he wants to implant Neuralink chips into quadriplegics who have brain or spinal injuries so that they can “control a computer mouse, or their phone, or really any device just by thinking.”

Neuralink has come under fire for its alleged treatment of monkeys, and the Physician’s Committee for Responsible Medicine called on Musk Wednesday to release details about experiments on monkeys that had resulted in their internal bleeding, paralysis, chronic infections, seizures, declining psychological health and death.

Jeff Miller/University of Wisconsin-Madison

Neuralink’s flashy presentations are unusual for companies in the medical devices space, said Anna Wexler, an assistant professor of Medical Ethics and Health Policy at the Perelman School of Medicine at the University of Pennsylvania. She said it’s risky to encourage people who have serious disabilities to get their hopes up, especially if they could possibly incur injuries as the technology is implanted during surgery.

Wexler encouraged people to put on their “skeptic hat” about Neuralink’s big claims.

“From an ethical perspective, I think that hype is very concerning,” she said. “Space or Twitter, that’s one thing, but when you come into the medical context, the stakes are higher.”

Chen, who specializes in brain-computer interfaces, said Neuralink’s implants would require subjects to undergo a very invasive procedure. Doctors would need to create a hole in the skill in order insert the device into the brain tissue itself.

But even so, she thinks some people would be willing to take the risk.

“There’s quite a few disorders such as epilepsy, Parkinson’s and obsessive-compulsive disorder in which people have received brain implants and the disorders have been treated quite successfully, allowing them to have an improved quality of life,” Chen said. “So I do feel that there is a precedent for doing this.”

Wexler said she believes the decision would ultimately come down to an individual patient’s personal risk-benefit calculation.

Neuralink is not the only company trying to innovate using brain-computer interfaces, and many have made big strides in recent years. Blackrock Neurotech is on track to bring a BCI system to market next year, which would make it the first commercially available BCI in history. Synchron received FDA approval in 2021 to begin a clinical trial for a permanently implanted BCI, and Paradromics is reportedly gearing up to begin in-human testing in 2023.

Continue Reading

Technology

Figure AI sued by whistleblower who warned that startup’s robots could ‘fracture a human skull’

Published

on

By

Figure AI sued by whistleblower who warned that startup's robots could 'fracture a human skull'

Startup Figure AI is developing general-purpose humanoid robots.

Figure AI

Figure AI, an Nvidia-backed developer of humanoid robots, was sued by the startup’s former head of product safety who alleged that he was wrongfully terminated after warning top executives that the company’s robots “were powerful enough to fracture a human skull.”

Robert Gruendel, a principal robotic safety engineer, is the plaintiff in the suit filed Friday in a federal court in the Northern District of California. Gruendel’s attorneys describe their client as a whistleblower who was fired in September, days after lodging his “most direct and documented safety complaints.”

The suit lands two months after Figure was valued at $39 billion in a funding round led by Parkway Venture Capital. That’s a 15-fold increase in valuation from early 2024, when the company raised a round from investors including Jeff Bezos, Nvidia, and Microsoft.

In the complaint, Gruendel’s lawyers say the plaintiff warned Figure CEO Brett Adcock and Kyle Edelberg, chief engineer, about the robot’s lethal capabilities, and said one “had already carved a ¼-inch gash into a steel refrigerator door during a malfunction.”

The complaint also says Gruendel warned company leaders not to “downgrade” a “safety road map” that he had been asked to present to two prospective investors who ended up funding the company.

Gruendel worried that a “product safety plan which contributed to their decision to invest” had been “gutted” the same month Figure closed the investment round, a move that “could be interpreted as fraudulent,” the suit says.

The plaintiff’s concerns were “treated as obstacles, not obligations,” and the company cited a “vague ‘change in business direction’ as the pretext” for his termination, according to the suit.

Gruendel is seeking economic, compensatory and punitive damages and demanding a jury trial.

Figure didn’t immediately respond to a request for comment. Nor did attorneys for Gruendel.

The humanoid robot market remains nascent today, with companies like Tesla and Boston Dynamics pursuing futuristic offerings, alongside Figure, while China’s Unitree Robotics is preparing for an IPO. Morgan Stanley said in a report in May that adoption is “likely to accelerate in the 2030s” and could top $5 trillion by 2050.

Read the filing here:

AI is turbocharging the evolution of humanoid robots, says Agility Robotics CEO

Continue Reading

Technology

Here are real AI stocks to invest in and speculative ones to avoid

Published

on

By

Here are real AI stocks to invest in and speculative ones to avoid

Continue Reading

Technology

The Street’s bad call on Palo Alto – plus, two portfolio stocks reach new highs

Published

on

By

The Street's bad call on Palo Alto – plus, two portfolio stocks reach new highs

Continue Reading

Trending